Qiagen, one of the main publicly traded medical diagnostics companies, has announced it hopes to have a test to detect the coronavirus by the end of this month.

The company is studying several options, including the DiagCORE® solution from Catalan company STAT-Dx (acquired by Qiagen in 2018).

DiagCORE® allows for fast molecular diagnosis of serious infectious diseases, which could be key in detecting the coronavirus quickly. The process is fully automated and gets results in roughly one hour, which are interpreted by integrated software and shown to healthcare professionals using an intuitive user interface. In this interview with CNBC TV, CEO Thierry Bernard demonstrates the system.

Qiagen is a CataloniaBio & HealthTech member and one of its main investors was the Ysios Capital fund, based in Barcelona.

You may also be interested in:

• Qiagen, one of the Catalan companies using Lean philosophy to become more competitive
• Catalan biomedical companies enter the promised land
• CataloniaBio 2017 Biosuccess Award goes to Mosaic Biomedicals and STAT-Dx